Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism

Clinical Endocrinology

Volumn 70, Issue 3, 2009, Pages 469-474

  Torun, Ayse Nur ^a,b   Kulaksizoglu, Sevsen ^b   Kulaksizoglu, Mustafa ^b   Pamuk, Baris Onder ^b   Isbilen, Elif ^b   Tutuncu, Neslihan Bascil ^b  

^a HARRAN UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPOTHYROIDISM; LIPID COMPOSITION; LIPID METABOLISM; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIOXIDANTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPOTHYROIDISM; LIPID METABOLISM; LIPID PEROXIDATION; MALONDIALDEHYDE; OXIDATIVE STRESS; TRIGLYCERIDES;

EID: 60349094682     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03348.x     Document Type: Article

References (46)

1. Krinsky, N.I. (1992) Mechanism of action of biological antioxidants. Proceedings of the Society for Experimental Biology and Medicine, 200, 248 254.
2. Oziol, L., Faure, P., Bertrand, N. et al. (2003) Inhibition of vitro macrophage induced low density lipoprotein oxidation by thyroid compounds. Journal of Endocrinology, 177, 137 146.
3. Freeman, B.A. Crapo, J.D. (1982) Biology of disease, free radicals and tissue injury. Laboratory Investigation, 47, 412 426.
4. Fernandez, V. Videla, L.A. (1989) Thyroid hormone, active oxygen, and lipid peroxidation. In : J. Miquel, A. T. Quintanilha, H. Weber eds. Handbook of Free Radicals and Antioxidants in Biomedicine. CRC Press, Florida. pp. 105 115.
5. Stevens, R.J., Nishio, M.L. Hood, D.A. (1995) Effect of hypothyroidism on the expression of cytochrome c and cytochrome c-oxidase in heart and muscle during development. Molecular Cell Biochemistry, 143, 119 127.
6. Pereira, B., Rosa, L.F., Safi, D.A. et al. (1994) Control of superoxide dismutase, catalase and glutathione peroxidase activities in rat lymphoid organs by thyroid hormones. Journal of Endocrinology, 140, 73 77.
7. Swaroop, A. Ramasarma, T. (1986) Heat exposure and hypothyroid conditions decrease hydrogen peroxide generation in liver mitochondria. Biochemical Journal, 226, 403 408.
8. Yilmaz, S., Ozan, S., Benzer, F. et al. (2003) Oxidative damage and antioxidant enzyme activities in experimental hypothyroidism. Cell Biochemistry and Function, 21, 325 330.
9. Dumitriu, L., Bartoc, R., Ursu, H. et al. (1988) Significance of high levels of serum malonyldialdehyde and ceruloplasmin in hyper- and hypothyroidism. Endocrinologie, 26, 35 38.
10. Costantini, F., Pierdomenico, S.D., De Cesare, D. et al. (1998) Effect of thyroid function on LDL oxidation. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 732 737.
11. Konukoglu, D., Ercan, M. Hatemi, H. (2002) Plasma viscosity in female patients with hypothyroidism: effects of oxidative stress and cholesterol. Clinical Hemorheology and Microcirculation, 27, 107 113.
12. Kebapcilar, L., Akinci, B., Bayraktar, F. et al. (2007) Plasma thiobarbituric acid-reactive substance levels in subclinical hypothyroidism. Medical Principles and Practice, 16, 432 436.
13. Pai, J.K., Pischon, T., Ma, J. et al. (2004) Inflammatory markers and the risk of coronary heart disease in men and women. New England Journal of Medicine, 351, 2599 2610.
14. Christ-Crain, M., Meier, C., Guglielmetti, M. et al. (2003) Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross sectional and a double-blind, placebo controlled trial. Atherosclerosis, 166, 379 386.
15. Luboshitzky, R. Herer, P. (2004) Cardiovascular risk factors in middle-aged women with subclinical hypothyroidism. Neuro Endocrinology Letters, 25, 262 266.
16. Perez, A., Cubero, J.M., Sucunza, N. et al. (2004) Emerging cardiovascular risk factors in subclinical hypothyroidism: lack of change after restoration of euthyroidism. Metabolism, 53, 1512 1515.
17. Erdem, T.Y., Ercan, M., Ugurlu, S. et al. (2008) Plasma viscosity, an early cardiovascular risk factor in women with subclinical hypothyroidism. Clinical Hemorheology Microcirculation, 38, 219 225.
18. Yoshioka, T., Kawada, K., Shimada, T. et al. (1979) Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. American Journal of Obstetrics and Gynecology, 135, 372 376.
19. Dumitriu, L., Bartoc, R. Ursu, H. (1988) Significance of high levels of serum malondialdehyde (MDA) and ceruloplasmin (CP) in hyper- and hypothyroidism. Revue Roumaine D'endocrinologie, 26, 35 38.
20. Venditti, P., Balestrieri, M., Di Meo, S. et al. (1997) Effect of thyroid state on lipid peroxidation, antioxidant defences, and susceptibility to oxidative stress in rat tissues. Journal of Endocrinology, 155, 151 157.
21. Polikar, R., Burger, A.G., Scherrer, U. et al. (1993) The thyroid and heart. Circulation, 87, 1435 1441.
22. Halliwell, B. Gutteridge, J.M.C. (1990) The role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymology, 186, 1 85.
23. Epstein, A.A. Lande, H. (1922) Studies on blood lipoids. The relation of cholesterol and protein deficiency to basal metabolism. Archives of Internal Medicine, 30, 563 577.
24. Mason, R.L., Hunt, H.M. Hurxthal, L. (1930) Blood cholesterol values in hyperthyrodism and hypothyroidism - their significance. New England Journal of Medicine, 203, 1273 1278.
25. Peters, J.P. Man, E.B. (1943) The interrelations of serum lipids in patients with thyroid disease. Journal of Clinical Investigation, 22, 715 720.
26. Kurland, G.S., Lucas, J.L. Freedberg, A.S. (1955) The metabolism of intravenously infused C14 labeled cholesterol in man before and after the induction of myxedema. Journal of Clinical Investigation, 34, 947.
27. Kurland, G.S., Lucas, J.L. Freedberg, A.S. (1961) The metabolism of intravenously infused C14 labeled cholesterol in euthyroidism and myxedema. Journal of Laboratory Clinical Medicine, 57, 574 585.
28. Chobanian, A.V., Burrows, B.A. Hollander, W. (1962) Body cholesterol metabolism in man. Measurement of the body cholesterol miscible pool and turnover rate. Journal of Clinical Investigation, 41, 1738 1744.
29. Rabinowitz, J.L. Myerson, R.M. (1963) Effect of dextrothyroxine on metabolism of C14-labeled cholesterol and tripalmitin. Journal of the American Medical Association, 183, 758 760.
30. Friedman, M., Byers, S.O. Rosenman, R.H. (1952) Changes in excretion of intestinal cholesterol and sterol digitonides in hyper- and hypothyroidism. Circulation, 5, 657 660.
31. Rosenman, R.H., Byers, S.O. Friedman, M. (1952) The mechanism responsible for the altered blood cholesterol content in deranged thyroid states. Journal of Clinical Endocrinology and Metabolism, 12, 1287 1299.
32. Kok, F.J., Van Poppel, G., Melse, J. et al. (1991) Do antioxidant and polyunsaturated fatty acids have a combined association with coronary atherosclerosis? Atherosclerosis, 31, 85 90.
33. Canaris, G.J., Manowitz, N.R., Mayor, G. et al. (2000) The Colorado thyroid disease prevalence study. Archives of Internal Medicine, 160, 526 534.
34. Vierhapper, H., Nardi, A., Grosser, P. et al. (2000) Low-density lipoprotein cholesterol in subclinical hypothyroidism. Thyroid, 10, 981 984.
35. Pirich, C., Mullner, M. Sinzinger, H. (2000) Prevalence and relevance of thyroid dysfunction in 1922 cholesterol screening participants. Journal of Clinical Epidemiology, 53, 623 629.
36. Milionis, H.J., Tambaki, A.P., Kanioglou, C.D. et al. (2005) Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect. Thyroid, 15, 455 460.
37. Hueston, W.J. Pearson, W.S. (2004) Subclinical hypothyroidism and the risk of hypercholesterolemia. Annals of Family Medicine, 2, 351 355.
38. Hollowell, J.G., Staehling, N.W., Flanders, W.D. et al. (2002) Serum TSH, T4, and thyroid antibodies in the United States population (1988-94): National Health and Nutrition Examination Survey (NHANES III). Journal of Clinical Endocrinology and Metabolism, 87, 489 499.
39. Fowler, P.B., Ikram, H. Banim, S.O. (1972) Serum-cholesterol, thyroid failure, and coronary-artery disease. Lancet, 25, 685.
40. Gursoy, A., Ozduman Cin, M., Kamel, N. et al. (2006) Which thyroid-stimulating hormone level should be sought in hypothyroid patients under 1-thyroxine replacement therapy? International Journal of Clinical Practice, 60, 655 659.
41. Hueston, W.J., King, D.E. Geesey, M.E. (2005) Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clinical Endocrinology, 63, 582 587.
42. Lee, W.Y., Suh, J.Y., Rhee, E.J. et al. (2004) Plasma CRP, apolipoprotein A-1, apolipoprotein B and Lpa levels according to thyroid function status. Archives of Medical Research, 35, 540 545.
43. Blake, G.J. Ridker, P.M. (2002) Inflammatory biomarkers and cardiovascular risk prediction. Journal of Internal Medicine, 252, 283 294.
44. Rawson, E., Freedson, P.S., Osganian, S.K. et al. (2003) Body mass index, but not physical activity, is associated with C-reactive protein. Medical Science Sports Exercise, 35, 1160 1166.
45. Ershler, W.B. Keller, E.T. (2000) Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annual Review of Medicine, 51, 245 270.
46. Selvin, E., Paynter, N.P. Erlinger, T.P. (2007) The effect of weight loss on C-reactive protein: a systematic review. Archives of Internal Medicine, 167, 31 39.